GSK Showcases RSV Vaccine and Portfolio; Novartis Gains Dual Approvals for Radioligand Therapy; AstraZeneca Announces Expanded Investment in China | CIIE Highlights

On the second day of the eighth China International Import Expo, Sina Medicine continued to review the first exhibits, premieres, and blockbuster products of major MNC pharmaceutical companies for its readers.

GSK: Showcases Approximately 20 Innovative Products

This year, GSK focuses on four major therapeutic areas: respiratory, immunology and inflammation, infectious diseases, HIV, and oncology, presenting approximately 20 innovative products and solutions at the Medical Equipment and Healthcare Products Exhibition of the CIIE.

GSK also brought a heavyweight innovative pipeline, including: the world's first approved and launched respiratory product, and the first Phase III clinical trial conducted in China.Respiratory Syncytial Virus (RSV) Vaccine; is expected to upgrade the treatment of severe asthma and chronic rhinosinusitis with nasal polyps to an injection every six months.Depemokimab (Depemokimab); The world's first anti-BCMA antibody-drug conjugate for multiple myelomaBelantamab Mafodotin (Belantamab Mafodotin), and is expected to achieve "functional cure" for chronic hepatitis BFunctional Cure"Antisense Oligonucleotide (ASO) Drug.

"CIIE Baby" Recombinant Zoster Vaccine (CHO Cell) and Mepolizumab Injection Debut with New Identities.

Recombinant Zoster Vaccine (CHO Cell)In October this year, it received approval from the China National Medical Products Administration (NMPA) to expand its indications for use in preventing shingles in adults aged 18 years and older who are at increased risk of developing shingles due to immunodeficiency or immunosuppression caused by known diseases or treatments (such as autologous hematopoietic stem cell transplantation).

Mepolizumab Injection has been approved in China for the treatment of adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps; in February this year, its marketing application for the treatment of chronic obstructive pulmonary disease (COPD) was also accepted in China.

In addition,Multiple Products for the Prevention and Treatment of Liver DiseasesThe drugs showcased at the CIIE booth include the recombinant hepatitis B vaccine (Saccharomyces cerevisiae), the nucleotide hepatitis B drug tenofovir disoproxil fumarate tablets, and antisense oligonucleotide (ASO) drugs that have the potential to achieve a "functional cure" for chronic hepatitis B.

In addition, GSK also showcasedHIV-1 Long-Acting RegimenIncluding the world's first long-acting HIV pre-exposure prophylaxis regimen, cabotegravir injection, as well as the long-acting treatment regimen combining cabotegravir injection and rilpivirine injection. This regimen is also the first complete HIV-1 long-acting (up to once every two months) injectable treatment regimen approved by China's National Medical Products Administration (NMPA).

Novartis: Radioligand Therapy Approved on the Eve of CIIE

At this year's CIIE, Novartis showcasedxRNA therapy, radioligand therapy, gene and cell therapyAdvanced therapies such as law, focusing on displaying nearly20 Blockbuster Innovative DrugsProducts, including multiple "world's first" innovative products and therapies.

Radioligand Therapy (RLT)It is a "targeted therapy" regimen that combines radionuclides with specific ligands targeting tumors to precisely attack cancer cells. Since its debut at the CIIE in 2021, RLT has become the highlight of Novartis' booth. Novartis'重磅创新药物 in radioligand therapy.Lutetium [177Lu] Texiviptide InjectionThe two indications were simultaneously approved in China just before the CIIE.

Pipeline Portfolio in Renal Therapy AreaAlso welcomed its first exhibition after being listed. The renal indications for the world's first oral complement B factor inhibitor targeting the complement alternative pathway, Iptacopan Hydrochloride Capsules, and China’s first and currently only approved highly selective endothelin A receptor antagonist for IgA nephropathy, Atrasentan Hydrochloride Tablets, were successively approved less than a year after their debut at the 2024 CIIE, truly becoming "CIIE babies."

AstraZeneca: Doubling Down on the Chinese Market, First Showcase of Two New Cancer Drugs

At the 8th China International Import Expo, AstraZeneca announced its latest achievements in expanding production layout in China and sustainable development, and showcased several innovative drugs.

On November 5, AstraZeneca signed a cooperation agreement with the Management Committee of Qingdao High-tech Industrial Development Zone, announcing an additional investment of approximately US$136 million to expand the production capacity of its Qingdao supply base. This expansion will further increase AstraZeneca's production capacity for inhalation aerosols, better meeting the treatment needs of patients with respiratory diseases such as asthma and COPD. Meanwhile, the Qingdao base project also adopts energy-saving technologies to help achieve near-zero carbon operations.

At this year's CIIE, AstraZeneca also showcased for the first time two innovative oncology drugs approved in China this year: Capivasertib Tablets and Durdalabtagene Autoleucel Injection.

Capisetron TabletsCapivasertib, developed by AstraZeneca, is a selective pan-AKT inhibitor that inhibits the PI3K/AKT/mTOR signaling pathway's abnormal activation by suppressing AKT kinase activity and blocking downstream mTOR protein expression. The abnormal activation of this pathway is one of the key mechanisms in the occurrence, progression, and drug resistance of breast cancer. Capivasertib is the first AKT-targeted inhibitor in China for the PAM (PI3K-AKT-mTOR) pathway and the world’s first approved AKT inhibitor for patients with CDK4/6i resistance.

DedabotumabDato-DXd is a TROP2-directed antibody-drug conjugate (ADC) that was approved in China this August. The global Phase III TROPION-Breast01 study showed that Dato-DXd significantly reduced the risk of disease progression or death by 37% in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer. In the study population, Dato-DXd extended the median progression-free survival (PFS) to 6.9 months, compared to 4.9 months for those receiving chemotherapy.

At the same time, innovative therapies in multiple newly expanded disease areas were also showcased at the booth.

Lilly: Tirzepatide Leads the Way, Accelerating Localization of the Entire Industrial Chain

At this year's CIIE, Lilly showcased several global innovative drugs, including Tirzepatide and Donanemab Injection; as well as Imlunestrant, an oral SERD for breast cancer which is about to be approved in China and make its debut at the CIIE, and Mirikizumab, an IL-23 inhibitor for treating inflammatory bowel disease.

Tirzepatide InjectionIt is one of the key products showcased this time. This drug has been approved in China for type 2 diabetes, long-term weight management, and obstructive sleep apnea (OSA), allowing it to precisely target the large population of people with diabetes and obesity.

Imlunestrant is an oral estrogen receptor degrader.In September this year, it received FDA approval for the treatment of adult patients with advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative, and carries an ESR1 gene mutation. The FDA's approval was primarily based on the results from the EMBER-3 trial in the population of MBC patients with ESR1 mutations (n=256). Analysis showed that Imlunestrant reduced the risk of disease progression or death by 38% compared to standard endocrine therapy. In MBC patients with ESR1 mutations, Imlunestrant significantly improved progression-free survival (PFS), with a median PFS of 5.5 months compared to 3.8 months in the control group (HR=0.62, 95% CI: 0.46-0.82; p=0.0008).

Boehringer Ingelheim: Breakthrough Therapy Unveiled

Boehringer Ingelheim will also bring several innovative drugs, including three representative products that have received "Breakthrough Therapy Designation," covering major diseases such as lung cancer, pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis (MASH).

Cancer Innovation DrugZong Ai TinibThe tablet was approved in China in August 2025 for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) activating mutations who have previously received at least one systemic therapy.Zong Ai TinibIt is the world's first and currently the only approved oral HER2 tyrosine kinase inhibitor. Zongaitinib demonstrates potent inhibitory activity against all major HER2 mutations, including the HER2 YVMA insertion allele.

Sina Medicine Comprehensive

Join the reader communication group:

Business Cooperation:Yang Xiaoyu 15210041717